IKT Earnings Prediction
The chart below shows how IKT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IKT sees a -6.37% change in stock price 10 days leading up to the earnings, and a -1.50% change 10 days following the report. On the earnings day itself, the stock moves by +4.98%. This data can give you a slight idea of what to expect for the next quarter's release.
IKT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
0.00
-100.00%
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.66
-40.54%
-9.59%
No Data Available
IKT Earnings Analysis
Inhibikase Therapeutics, Inc. Common Stock Corporation (IKT.O) Earnings Conference Call
Positive
{
- Net loss decreased from $5.8 million in Q2 2023 to $5.0 million in Q2 2024, showcasing improved financial performance.
- Milestone achieved in Parkinson's disease trial, indicating progress in clinical development.
- discussions with FDA for pulmonary arterial hypertension drug, indicating potential for regulatory approval.
- Raised funds extend cash runway into December 2024, supporting upcoming milestones.
- Reduction from $4.5 million to $3.1 million in Q2 2024, demonstrating cost management efforts." }
Negative
- 41 mild and 8 moderate adverse events related to risvodetinib treatment
- 6 participants withdrawn from the trial without completing 12 weeks of dosing
- Legal and consulting fees increased by $0.4 million in selling, general, and administrative expenses
IKT FAQs
How does IKT typically perform around its earnings report dates?
Is Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IKT Earning Call Sentiment
Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript
1.0x
00:00
00:00
IKT.O
-1.71%Positive
The earnings call presents a mixed picture. Financial performance shows a decrease in net loss and R&D expenses, indicating cost management. However, funding challenges and reliance on FDA approval pose risks. The market opportunity in PAH is significant, but competitive. Q&A reveals uncertainties in trial timelines and patient transitions. Overall, the lack of clear guidance and potential funding issues balance out positive developments, resulting in a neutral sentiment.
